ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2114

Exposure to Carbamylated Self- and Non-Self-Proteins Can Lead to a Break-of -Tolerance and the Induction of Autoimmunity

Jacqueline Dekkers1, Marije K. Verheul2, Jeroen Stoop3, Bisheng Liu4, Peter A. van Veelen5, Martin Hegen6, Stephen Rapecki7, Tom WJ Huizinga2, Leendert A. Trouw4 and René Toes4, 1Rheumatology, Department of Rheumatology, Leiden University Medical Center (LUMC), Leiden, Netherlands, 2Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, 3Leiden University Medical Center (LUMC), Leiden, Netherlands, 4Rheumatology, Leiden University Medical Center, Leiden, Netherlands, 5Immunohematology and Bloodbank, Leiden University Medical Center, Leiden, Netherlands, 6Inflammation, Wyeth Pharmaceuticals, Cambridge, MA, 7UCB Pharma, Slough, United Kingdom

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: Auto-immunity, autoantibodies, autoantigens and rheumatoid arthritis (RA), B cell tolerance

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 15, 2016

Title: B Cell Biology and Targets in Autoimmune Disease - Poster II: Rheumatoid Arthritis and Other Rheumatic Diseases

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: Autoantibodies are an important hallmark of Rheumatoid Arthritis (RA). Approximately 50% of RA patients harbor anti-carbamylated protein (CarP) antibodies. These autoantibodies target proteins that are modified through a posttranslational modification named carbamylation or homocitrullination. It has been postulated that posttranslational modifications can play a role in the breach of tolerance towards self-antigens. These anti-carbamylated protein (CarP) antibodies can recognize both carbamylated foreign- and self-proteins. It is currently unknown whether carbamylated foreign-proteins can evoke an anti-CarP autoimmune response or whether this can only be facilitated through carbamylation of self-proteins. Therefore we studied whether carbamylation of self- and foreign-proteins can drive loss of B-cell tolerance to carbamylated proteins.

Methods: Mice were immunized with carbamylated- or non-modified (auto)antigens and analyzed for autoantibody responses. Anti-CarP hybridomas were sequenced using single cell PCR-based antibody cloning technology. Mass spectrometry was used to identify carbamylated self-proteins in rheumatic joint tissue. Serum reactivity towards Ca-human serum albumin and Ca-FCS was determined for 100 RA-patients of the Leiden Early Arthritis Cohort and 40 healthy subjects.

Results: Immunization with carbamylated self-proteins (Albumin) resulted in a potent anti-CarP antibody response against both carbamylated foreign- and self-proteins. Likewise, immunization with carbamylated foreign-proteins (OVA) induced a strong anti-CarP response against both carbamylated foreign- and self-proteins. Similar to serum anti-CarP antibodies, murine monoclonal anti-CarP antibodies were highly specific and cross-reactive to multiple carbamylated (auto)antigens. Although citrulline greatly resembles homocitrulline residues in structure, anti-CarP antibodies differ in antigen recognition profile from ACPA as they are able to discriminate between citrullinated and homocitrullinated forms of the same protein. Interestingly, we were able to identify carbamylated-albumin, in RA synovial tissue, indicating that albumin is present in carbamylated form locally in the inflamed joint. Moreover, we detected antibody responses against carbamylated-human albumin were observed in 38% of early RA patients from the Leiden Early Arthritis Clinic.

Conclusion: These results show that not only carbamylated self-, but also carbamylated non-self-proteins can lead to a breach of B-cell tolerance leading to B-cell responses against carbamylated self-proteins. These results indicate that auto-reactive B-cells to carbamylated proteins as well as it is underlying T-cell response could find its origin in the exposure to carbamylated foreign-proteins.


Disclosure: J. Dekkers, None; M. K. Verheul, None; J. Stoop, None; B. Liu, None; P. A. van Veelen, None; M. Hegen, Pfizer Inc, 3; S. Rapecki, None; T. W. Huizinga, None; L. A. Trouw, None; R. Toes, None.

To cite this abstract in AMA style:

Dekkers J, Verheul MK, Stoop J, Liu B, van Veelen PA, Hegen M, Rapecki S, Huizinga TW, Trouw LA, Toes R. Exposure to Carbamylated Self- and Non-Self-Proteins Can Lead to a Break-of -Tolerance and the Induction of Autoimmunity [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/exposure-to-carbamylated-self-and-non-self-proteins-can-lead-to-a-break-of-tolerance-and-the-induction-of-autoimmunity/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/exposure-to-carbamylated-self-and-non-self-proteins-can-lead-to-a-break-of-tolerance-and-the-induction-of-autoimmunity/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology